Orthocon, a manufacturer of products that stop bone bleeding, has entered into a worldwide licence agreement to develop and commercialise Bezwada Biomedical’s technology for bone applications.
Bezwada’s proprietary technology platforms are comprised of bioabsorbable and biocompatible polyurethanes, and polyamides derived from hydrolysable isocyanates.
The technologies can be used to create absorbable surgical devices for a variety of applications, including structural support, fixation and drug delivery.
Orthocon president and CEO John Pacifico said the strategic partnership is an important milestone for the company as it enhances the company’s technological capabilities and product pipeline.
The company has recently initiated development programmes to advance the Bezwada technology towards commercialisation, Orthocon said.